Overall, Our evidence suggests that Omaveloxolone may enhance the survival of dopaminergic neurons in the substantia nigra of PD mice and reduce neurological deficits via the Keap1-Nrf2/ARE signaling pathway. This evidence concerns the gene KEAP1 and Parkinson disease.